Publications
The following publications highlight HistoRx's AQUA®
technology:
Click here to view the publications grouped by topic vs year.
Harigopal, M., W. E. Barlow, et al. "Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows That Both High and Low Levels of HER2 Are Associated with Poor Outcome." Am J Pathol.
S.J. Aitken, J.S. Thomas,
S.P. Langdon, D.J. Harrison and D. Faratian,Annals of Oncology,
doi:10.1093/annonc/mdp427
Jingchun Gao, Zhong Zheng, Bhupendra Rawal, Michael J. Schell, Gerold Bepler and Eric B. Haura. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biology & Therapy, September 1,2009
Dana Faratian, Alexey Goltsov, Galina Lebedeva, Anatoly Sorokin, Stuart Moodie, Peter Mullen,
Charlene Kay, In Hwa Um, Simon Langdon, Igor Goryanin, and David J. Harrison. Systems Biology Reveals New Strategies for Personalizing
Cancer Medicine and Confirms the Role of PTEN in
Resistance to Trastuzumab. AACR Journals Systems Biology and Emerging Technologies, 2009 Jul 28.
Dana Faratian, Robert G. Clyde, John W. Crawford and David J. Harrison. Systems pathology—taking molecular
pathology into a new dimension. Nature Reviews Clinical Oncology 2009 Jul.
Lindsay J, Jiao X, Sakamaki T, Casimiro MC, Shirley LA, Tran TH , Ju X, Liu M, Li Z, Wang C, Katiyar S, Rao M, Allen KG, Glazer RI, Ge C, Stanley P, Lisanti MP, Rui H and Pestell RG. ErbB2 induces Notch1 activity and function in breast cancer cells. Clinical and Translational Science 2009, in press.
Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol. 2009 Jan; 16(1):200-7.
Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A and Wilding G. Evaluation of mRNA by Q-RTPCR and Protein Expression by AQUA of M2 Sub-unit of Ribonucleotide Reductase (RRM2) in Human Tumors. 2009 Jan;17(1):23-30.
Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Thomas Jefferson University. Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists Cancer Research 68, 5628-5638. 2008 Jul 15.
Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas Invest New Drugs. 2008 Aug;26(4):369-79. Epub 2008 Feb 16.
Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Kowalski D, Diamandis
EP, Dimopoulos MA. Human tissue kallikrein 7, a novel biomarker for
advanced ovarian carcinoma using a novel in situ
quantitative method of protein expression Ann Oncol. 2008 Jul;19(7):1271-7. Epub 2008 Mar 5.
Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions Mod Pathol. 2008 Jun 13. [Epub ahead of print]
Psyrri A, Egleston B, Weinberger P, Yu Z, Kowalski D, Sasaki C, Haffty B, Rimm D,
Burtness B. Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content
in an Oropharyngeal Cancer Tissue Microarray. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1486-92.
Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate Synthase in Situ Protein Expression and
Survival in Stage I Nonsmall-Cell Lung Cancer Cancer. 2008 Jun 15;112(12):2765-73.
Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Estrogen Receptor Co-Activator (AIB1) Protein Expression
by Automated Quantitative Analysis (AQUA) in a Breast
Cancer Tissue Microarray and Association with Patient Outcome Breast Cancer Research and Treatment 2008 May 13; DOI 10.1007/s10549-008-0063-9
Kreizenbeck GM, Berger AJ, Subtil A, Rimm DL, Gould Rothberg BE. Prognostic Significance of Cadherin-Based Adhesion
Molecules in Cutaneous Malignant Melanoma Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):949-58.
Nadler Y, Camp RL, Gitnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression Patterns and Prognostic Value of Bag-1 and Bcl-2 in
Breast Cancer Breast Cancer Res. 2008;10(2):R35. Epub 2008 Apr 23.
Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H, Fuchs SY. Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3 Beta Impairs
Degradation of Prolactin Receptor. Cancer Res. 2008 Mar 1;68(5):1354-61
Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman
D, Camp RL, Rimm DL. Quantitative Justification of the Change from 10% to 30% for Human Epidermal
Growth FactorReceptor 2 Scoring in the American Society of Clinical
Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in
Breast Cancer and its Implications forTissue Microarray Based Assessment of
Outcome. J Clin Oncol. 2007 Dec 1;25(34):5418-25.
Kidd M, Modlin IM, Shapiro MD, Camp RL, Mane SM, Usinger W, Murren JR. CTGF, Intestinal Stellate Cells and Carcinoid Fibrogenesis. World J Gastroenterol. 2007 Oct 21;13(39):5208-16.
Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener PA, Moch H, Rubin MA. Automated Immunofluorescence Analysis Defines
Microvessel Area as a Prognostic Parameter in
Clear Cell Renal Cell Cancer Human Pathology 2007 38, 1454-1462
Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, Perlee LT, Quezado M, Spollen LE, Wustman BA, Schiffmann R. Cellular and tissue localization of globotriaosylceramide
in Fabry disease Springer. Virchows Arch DOI 10.1007/s00428-007-0468-6
Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, Garcia-Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population-based analysis. International Journal of Cancer. 121(5): 1079-85 2007 Sep
Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. Journal of Clinical Oncology 25(21): 3007-3014. 2007 Jul 20
Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B. Bimodal population or pathologist artifact? J Clin Oncol. 2007 Jun 10;25(17):2487-8.
Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007:25:1, 19 - 26
Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Laboratory Investigation 87(7): 662-669. 2007 Jul
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. NA Yale University. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Research 67(7):2932-7. 2007 Apr 1
Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL Quantitative analysis of estrogen receptor heterogeneity in breast cancer Laboratory Investigation 10.1038/labinvest.3700543, March 5, 2007
Gazdar AF. DNA repair and survival in lung cancer--the two faces of Janus. New England Journal of Medicine.356(8):771-3, February 22, 2007
Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. New England Journal of Medicine 356(8):800-8, February 22, 2007.
Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated
Protein Kinase Signaling Shows a New Type of Melanoma Cancer Research 67(4): 1502-1512, February 15, 2007
Pozner-Moulis S, Cregger M, Camp RL, Rimm DL Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model Laboratory Invetigation (2007) 1-10 0023-6837/07, January 29, 2007
Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G The X-linked Inhibitor of Apoptosis Protein (XIAP) is Up-regulated in Metastatic Melanoma, and XIAP Cleavage by Phenoxodiol is Associated with Carboplatin Sensitization Journal of Translational Medicine 2007, 5:6 10.1186/1479-5876-5-6, January 26, 2007
Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. New England Journal of Medicine 356(8):800-8, February 22, 2007.
Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, Economopoulos T, Dimopoulos MA Analysis of p53 Protein Expression Levels on Ovarian Cancer Tissue Microarray using Automated Quantitative Analysis Elucidates Prognostic Patient Subsets Annals of Oncology 10.1093/annonc/mdl479, January 13, 2007
2006 Publications
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL Classification of Breast Cancer Using Genetic Algorithms and
Tissue Microarrays. Clinical Cancer Research 12(21): 6459-6468, November 1, 2006.
Kidd, M. Modlin IM, Mane SM, Camp RL, Eick G, Latich I. The Role of Genetic Markers—NAP1L1, MAGE-D2, and MTA1—In Defining Small-Intestinal Carcinoid Neoplasia. Annals of Surgical Oncology 13(2): 253-262, 2006.
Giltnane JM, Murren JR, Rimm DL, King BL. AQUA and FISH Analysis of HER-2/Neu Expression and Amplification in a Small Cell Lung Carcinoma Tissue Microarray. Histopathology 49: 161-169, 2006.
Bamias A, Yu Z, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulus MA, Psyrri A. Automated Quantitative Analysis of DCC Tumor Suppressor Protein in Ovarian Cancer Tissue Microarray shows Association with β-catenin Levels and Outcome in Patients with Epithelial Ovarian Cancer. Annals of Oncology 10.1093/annonc/mdl310, September 13, 2006.
Rimm, DL. What Brown Cannot Do for You. [Commentary.] Nature Biotechnology 24(8): 914-916, August, 2006.
McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma. Clinical Cancer Research 12(12): 3856-3863, June 15, 2006.
Psyrri A, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. Cancer Epidemiology Biomarkers & Prevention15(6): 1179-1183, June, 2006.
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In Situ Analysis of Beta-Catenin Expression in Breast Cancer Shows Decreased Expression is Associated With Poor Outcome. Cancer Research, 66(10): 5487-5494, May 15, 2006.
Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular Endothelial Growth Factor, FLT-1, and FLK-1 Analysis in a Pancreatic Cancer Tissue Microarray. Cancer 106(8): 1677-1684, April 15, 2006.
Kidd M, Modlin IM, Mane SM, Camp RL, Eick GN, Latich I, Zikusoka MN. Utility of Molecular Genetic Signatures in the Delineation of Gastric Neoplasia. Cancer 106(7):1480-1488, April 1, 2006.
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers With Favorable Prognosis. Journal of Clinical Oncology 24(5): 736-747, February 10, 2006.
2005 Publications
Dolled-Filhart MP, Rimm DL, Stroobant P. [Review.] Quantitative In Situ Cancer Proteomics: Molecular Pathology Comes of Age With Automated Tissue Microarray Analysis. Personalized Medicine 2(4): 291-300, 2005.
Henson DE. Back to the Drawing Board on Immunohistochemistry and Predictive Factors. [Editorial.] Journal of the National Cancer Institute 97(24): 1796-1797, December 21, 2005.
McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal of the National Cancer Institute 97(24): 1808-1815, December 21, 2005.
Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients With Epithelial Ovarian Cancer. Clinical Cancer Research 11(24): 8637-8643, December 15, 2005.
Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated Quantitative Analysis of Activator Protein-2-Alpha Subcellular Expression In Melanoma Tissue Microarrays Correlates With Survival Prediction. Cancer Research 65(23):11185-11192, December 1, 2005.
Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor P27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research 11(23): 8384-8390, December 1, 2005.
Siddiqui S, Pawelek J, Handerson T, Lin C-Y, Dickson RB, Rimm DL, Camp RL. Coexpression of Beta-1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome. Cancer Epidemiology Biomarkers & Prevention14(11): 2517-2523, November, 2005.
Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research 11(16): 5856-5862, August 15, 2005.
Merlino G. Cancer biology: the weakest link? Nature. 2005 Jul 7;436(7047):33-5.
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma. Nature 436: 117-122, July 7, 2005.
Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated With Clinically Aggressive Disease. Cancer Research 65: 5578-5587, July 1, 2005.
McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clinical Cancer Research 11(14): 5188-5194, June 15, 2005.
Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases is Predictive of Survival in Invasive Ductal Breast Cancer. Clinical Cancer Research 11: 4083-4089, June 1, 2005.
Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Beta-Catenin Functions Mainly as an Adhesion Molecule in Patients With Squamous Cell Cancer of the Head and Neck. Clinical Cancer Research 11: 2471-2477, April 1, 2005.
Yu Z, Weinberger PM, Haffty BG, Sasaki C, Zerillo C, Joe J, Kowalski D, Dziura J, Camp RL, Rimm DL, Psyrri A. Cyclin D1 is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research 11:1160-1166, February 1, 2005.
Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite Instability and Gene Mutations in Transforming Growth Factor-Beta Type II Receptor are Absent in Small Bowel Carcinoid Tumors. Cancer 103(2): 229-236, January 15, 2005.
2004 Publications
DiVito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated Quantitative Analysis of Tissue Microarrays Reveals an Association Between High Bcl-2 Expression and Improved Outcome in Melanoma. Cancer Research 64: 8773-8777, December 1, 2004.
Berger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL. Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association With Early-Stage Disease and Improved Outcome. Cancer Research 64: 8767-8772, December 1, 2004.
Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clinical Cancer Research 10: 7252-7259, November 1, 2004.
DiVito KA, Charette LA, Rimm DL, Camp RL. Long-Term Preservation of Antigenicity on Tissue Microarrays. Laboratory Investigation 84(8): 1071-1078, June 14, 2004.
Chiriboga L, Osman I, Mikhail M, Lau C. [Letter to the Editor.] Tissue Microarrays, Tread Carefully. Laboratory Investigation 84: 1677, April, 2004.
2003 Publications
Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome. Cancer Research 63: 1445-1448, April 1, 2003.
2002 Publications
Camp RL, Chung GG, Rimm DL. Automated Subcellular Localization and Quantification of Protein Expression in Tissue Microarrays. Nature Medicine 8(11): 1323-1327, November, 2002.